Kestra Revenue Jumps 52% in Fiscal Q1
Kestra Medical Technologies (NASDAQ:KMTS), a developer of wearable cardiac defibrillators and digital cardiac care solutions, released its results for Q1 FY2026 on September 11, 2025. The headline news was a 52% year-over-year increase in revenue, alongside a raised annual revenue outlook to $88 million for FY2026. The quarter showed strong demand but also highlighted ongoing pressure from rising expenses and widening losses.
Kestra Medical Technologies focuses on wearable cardioverter defibrillators (WCDs), specifically the ASSURE system, which helps protect cardiac patients from sudden cardiac arrest. The ASSURE system is a wearable medical device that monitors for abnormal heart rhythms and can deliver life-saving therapy automatically when needed.
The company’s strategy centers on five key areas: expanding its U.S. and international presence, innovating with advanced cardiac monitoring and digital health, solidifying regulatory and payor coverage, delivering scalable operations, and strengthening its revenue cycle management. Kestra’s success is tied to the adoption of the ASSURE system, payer contract coverage, and its ability to increase the efficiency of commercial operations while maintaining close relationships with healthcare providers.
Source Fool.com
